Eli Lilly and Company has become a key player in the manufacturing of tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant capacity to improve glycemic control and reduce cardiovascular risks. The sophisticated synthe